How to Buy Gujarat Themis Biosyn Ltd Shares?
You can easily buy the stocks/shares of Gujarat Themis Biosyn Ltd (GUJTHEM) on Tickertape or through broker platform by opening a Demat & Trading account onlineWhat is the Share Price of Gujarat Themis Biosyn Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of GUJTHEM as on 15th May 2025 is ₹320.30What is the return on Gujarat Themis Biosyn Ltd share?
The past returns of Gujarat Themis Biosyn Ltd (GUJTHEM) share are- Past 1 week: N/A
- Past 1 month: -93.29
- Past 3 months: 34.84
- Past 6 months: 2.48
- Past 1 year: 6.77
- Past 3 years: 2977.25
- Past 5 years: 7090.54
What is the Dividend yield % on Gujarat Themis Biosyn Ltd share?
The current dividend yield of Gujarat Themis Biosyn Ltd (GUJTHEM) is 0.27What is the Market Cap of Gujarat Themis Biosyn Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Gujarat Themis Biosyn Ltd (GUJTHEM) is ₹2663.11Cr as of 15th May 2025What is the 52 Week High and Low of Gujarat Themis Biosyn Ltd?
The 52-week high and low of Gujarat Themis Biosyn Ltd (GUJTHEM) is ₹390 and ₹192.35.What is the PE and PB ratio of Gujarat Themis Biosyn Ltd?
The P/E (price-to-earnings) and P/B (price-to-book) ratios of Gujarat Themis Biosyn Ltd are 54.61 and 13.22 respectively.Which sector does Gujarat Themis Biosyn Ltd belong to?
Gujarat Themis Biosyn Ltd (GUJTHEM) belongs to the Health Care sector & Pharmaceuticals sub-sector.What are the peers or stocks similar to Gujarat Themis Biosyn Ltd?
The peers or stocks similar to Gujarat Themis Biosyn Ltd are: and many others.Can't decide whether or not to buy Gujarat Themis Biosyn Ltd?
Worry no more! Login to Tickertape and check out Gujarat Themis Biosyn Ltd (GUJTHEM) scorecard & all the relevant insights today5. Test Stocks FAQ What is the 52 Week High and Low of Gujarat Themis Biosyn Ltd?
The 52-week high and low of Gujarat Themis Biosyn Ltd (GUJTHEM) is ₹390 and ₹192.35.1. Test Stocks FAQ for Gujarat Themis Biosyn Ltd Shares?
You can easily buy the stocks/shares of Gujarat Themis Biosyn Ltd (GUJTHEM) on Tickertape or through broker platform by opening a Google & Trading account online3. Test Stocks FAQ What is the Share Price of Gujarat Themis Biosyn Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of GUJTHEM as on 15th May 2025 is ₹320.30
Gujarat Themis Biosyn Ltd
GUJTHEM Share Price
320.301.63% (+5.15)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
GUJTHEM Performance & Key Metrics
GUJTHEM Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 54.62 | 13.22 | 0.27% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.21 | 6.66 | 0.83% |
GUJTHEM Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
GUJTHEM Company Profile
The company makes bulk drugs. It's R&D division focuses on developing fermentation cultures. The Company's products include Rifamycin-S, which is an intermediate for Rifampicin for the treatment of tuberculosis (TB), and Lovastatin.
SUNPHARMA
PE Ratio
37.00
37.00
1Y Return
11.72%
11.72%
Buy Reco %
89.19
89.19
CIPLA
PE Ratio
23.03
23.03
1Y Return
2.55%
2.55%
Buy Reco %
71.05
71.05
DRREDDY
PE Ratio
20.02
20.02
1Y Return
11.76%
11.76%
Buy Reco %
82.05
82.05
TORNTPHARM
PE Ratio
57.53
57.53
1Y Return
13.13%
13.13%
Buy Reco %
67.74
67.74
MANKIND
PE Ratio
49.29
49.29
1Y Return
6.30%
6.30%
Buy Reco %
—
—
GUJTHEM Sentiment Analysis
GUJTHEM Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
GUJTHEM Stock Summary · January 2025
Company is navigating a complex landscape characterized by declining market share in deposits, challenges in meeting Priority Sector Lending (PSL) obligations, and fluctuations in current account flows. Despite these hurdles, the bank is focusing on enhancing customer engagement and service delivery to drive deposit growth, with recent monthly inflows showing a positive trend. The management emphasizes a strategic approach to maintaining profitability over aggressive expansion, particularly in light of competitive pressures and a tight liquidity environment. Efforts to improve operational efficiencies through digitization and a commitment to stable cost management are underway, alongside a proactive strategy to reduce borrowings and strengthen the balance sheet. Overall, while facing short-term challenges, the bank remains optimistic about future performance and is committed to achieving sustainable growth through strategic investments and improved customer outreach.
GUJTHEM Stock Growth Drivers
GUJTHEM Stock Growth Drivers
4Focus on Sustainable Growth
Company is prioritizing profitable growth over mere expansion, emphasizing a strategy that encourages ground-level teams
Stable Financial Metrics
The company has maintained a return on assets (ROA) of 1.9% post-merger, showcasing stability in
GUJTHEM Stock Challenges
GUJTHEM Stock Challenges
4Deposit Growth Shortfalls
The company has experienced deposit growth that has not met expectations, attributed to seasonal trends
Loan Growth Concerns
There is uncertainty regarding the company's loan deposit ratio (LDR) and its implications for loan
GUJTHEM Forecast
What are forecasts?
What are forecasts?
Forecasting uses historical data as inputs to make informed predictive estimates determining the direction of future trends. Price, revenue & earnings forecasts represent where the stock level, business prospects and profits are potentially expected to be at the end of the forecast period
GUJTHEM Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
GUJTHEM
GUJTHEM
Income
Balance Sheet
Cash Flow
Annual Normal View
GUJTHEM Income Statement
GUJTHEM Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 36.05 | 38.97 | 43.26 | 86.82 | 93.83 | 118.90 | 154.98 | 174.20 | 153.23 | 153.23 | ||||||||||
Raw Materials | 1.49 | 2.15 | 1.30 | 15.44 | 15.75 | 21.75 | 29.73 | 25.67 | 81.96 | 81.96 | ||||||||||
| Power & Fuel Cost | 17.99 | 19.33 | 20.20 | 22.86 | 16.57 | 21.73 | 26.41 | 26.53 | ||||||||||||
| Employee Cost | 4.42 | 4.46 | 5.17 | 6.43 | 7.11 | 7.08 | 7.75 | 10.21 | ||||||||||||
| Selling & Administrative Expenses | 0.85 | 1.10 | 1.39 | 1.64 | 1.86 | 2.31 | 6.66 | 8.51 | ||||||||||||
| Operating & Other expenses | 4.90 | 5.52 | 5.62 | 6.91 | 8.94 | 3.94 | 4.20 | 20.18 | ||||||||||||
EBITDA | 6.40 | 6.41 | 9.58 | 33.54 | 43.60 | 62.09 | 80.23 | 83.10 | 71.27 | 71.27 | ||||||||||
| Depreciation/Amortization | 1.12 | 1.15 | 1.22 | 1.36 | 1.73 | 2.23 | 2.58 | 3.54 | 5.37 | 5.38 | ||||||||||
| PBIT | 5.28 | 5.26 | 8.36 | 32.18 | 41.87 | 59.86 | 77.65 | 79.56 | 65.90 | 65.89 | ||||||||||
| Interest & Other Items | 0.41 | 0.42 | 0.16 | 0.92 | 0.98 | 0.83 | 0.18 | 0.23 | 0.36 | 0.36 | ||||||||||
| PBT | 4.87 | 4.84 | 8.20 | 31.26 | 40.89 | 59.03 | 77.47 | 79.33 | 65.54 | 65.53 | ||||||||||
| Taxes & Other Items | 0.50 | 0.97 | 1.79 | 7.59 | 10.71 | 15.41 | 19.50 | 20.18 | 16.77 | 16.77 | ||||||||||
| Net Income | 4.37 | 3.87 | 6.41 | 23.67 | 30.18 | 43.62 | 57.97 | 59.15 | 48.77 | 48.76 | ||||||||||
| EPS | 0.40 | 0.36 | 0.59 | 2.17 | 2.77 | 4.00 | 5.32 | 5.43 | 4.48 | 4.47 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.22 | 0.00 | 1.47 | 0.72 | 3.33 | 0.67 | 0.33 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.10 | 0.00 | 0.37 | 0.14 | 0.61 | 0.15 | 0.07 |
GUJTHEM Company Updates
FY 2025FY 2025
Investor Presentation
May 20PDF
GUJTHEM Stock Peers
What are peers and why compare against them?
What are peers and why compare against them?
A stock's peers are companies which have similar business interests, operations and belong to the same industry sector. Comparing various metrics against peers can give valuable insights on whether the company's stock is over/under-valued and the company's growth outlook vs the industry as a whole
GUJTHEM Past Performance & Peer Comparison
GUJTHEM Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Gujarat Themis Biosyn Ltd | 54.61 | 13.22 | 0.27% |
| Sun Pharmaceutical Industries Ltd | 37.00 | 6.03 | 0.95% |
| Cipla Ltd | 23.03 | 4.53 | 1.06% |
| Dr Reddy's Laboratories Ltd | 20.02 | 4.01 | 0.59% |
GUJTHEM Stock Price Comparison
Compare GUJTHEM with any stock or ETFCompare GUJTHEM with any stock or ETF
GUJTHEM
GUJTHEM Holdings
GUJTHEM Shareholdings
What are shareholdings?
What are shareholdings?
Apart from retail investors, a company’s shares are held by promoters, foreign & domestic institutions (large investors) and mutual funds. Promoters are the ship captains and control the company’s direction. Along with institutional and mutual fund holdings, a change in their holdings can indicate performance outlook for the stock
GUJTHEM Promoter Holdings Trend
GUJTHEM Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
GUJTHEM Institutional Holdings Trend
GUJTHEM Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
GUJTHEM Shareholding Pattern
GUJTHEM Shareholding Pattern
GUJTHEM Shareholding History
GUJTHEM Shareholding History
Foreign Institutions
Mutual Funds Invested in GUJTHEM
Mutual Funds Invested in GUJTHEM
No mutual funds holding trends are available
Top 3 Mutual Funds holding Gujarat Themis Biosyn Ltd
| Funds (Top 3) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.1135% | Percentage of the fund’s portfolio invested in the stock 3.52% | Change in the portfolio weight of the stock over the last 3 months 0.76% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 12/40 (+2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.2974% | Percentage of the fund’s portfolio invested in the stock 0.44% | Change in the portfolio weight of the stock over the last 3 months 0.09% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 26/48 (-5) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0004% | Percentage of the fund’s portfolio invested in the stock 0.06% | Change in the portfolio weight of the stock over the last 3 months 0.06% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 83/102 (+2) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing GUJTHEM stock
smallcases containing GUJTHEM stock
Looks like this stock is not in any smallcase yet.
GUJTHEM Events
GUJTHEM Events
GUJTHEM Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
What are dividends?
What are dividends?
Dividends are a portion of earnings that a company distributes to all its shareholders every year. Dividend return is one of the most important things to be considered while investing for long term. It’s the additional return on top of what investors earn through price appreciation
GUJTHEM Dividend Trend
No dividend trend available
GUJTHEM Upcoming Dividends
GUJTHEM Upcoming Dividends
No upcoming dividends are available
GUJTHEM Past Dividends
GUJTHEM Past Dividends
Cash Dividend
Ex DateEx DateJul 15, 2024
Final
Final | Div/Share: ₹0.25
Dividend/Share
₹0.25
Ex DateEx Date
Jul 15, 2024
Cash Dividend
Ex DateEx DateJul 14, 2024
Final
Final | Div/Share: ₹0.25
Dividend/Share
₹0.25
Ex DateEx Date
Jul 14, 2024
Cash Dividend
Ex DateEx DateFeb 21, 2024
Interim
Interim | Div/Share: ₹0.75
Dividend/Share
₹0.75
Ex DateEx Date
Feb 21, 2024
Cash Dividend
Ex DateEx DateAug 29, 2022
Final
Final | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
Aug 29, 2022
Cash Dividend
Ex DateEx DateNov 24, 2021
Special
Special | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Nov 24, 2021
GUJTHEM Stock News & Opinions
GUJTHEM Stock News & Opinions
Articles & Videos
Corporate
Board of Gujarat Themis Biosyn recommends final dividend
Gujarat Themis Biosyn announced that the Board of Directors of the Company at its meeting held on 20 May 2025, inter alia, have recommended the final dividend of Rs 0.67 per equity Share (i.e. 67%) , subject to the approval of the shareholders.Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Earnings
Gujarat Themis Biosyn standalone net profit declines 24.48% in the March 2025 quarter
Net profit of Gujarat Themis Biosyn declined 24.48% to Rs 12.00 crore in the quarter ended March 2025 as against Rs 15.89 crore during the previous quarter ended March 2024. Sales declined 10.16% to Rs 37.74 crore in the quarter ended March 2025 as against Rs 42.01 crore during the previous quarter ended March 2024. For the full year,net profit declined 17.56% to Rs 48.77 crore in the year ended March 2025 as against Rs 59.16 crore during the previous year ended March 2024. Sales declined 11.20% to Rs 150.80 crore in the year ended March 2025 as against Rs 169.82 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales37.7442.01 -10 150.80169.82 -11 OPM %42.5049.82 -45.6546.37 - PBDT17.3221.88 -21 70.9182.88 -14 PBT16.0920.96 -23 65.5479.34 -17 NP12.0015.89 -24 48.7759.16 -18 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Gujarat Themis Biosyn to announce Quarterly Result
Gujarat Themis Biosyn will hold a meeting of the Board of Directors of the Company on 20 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Gujarat Themis Biosyn standalone net profit declines 0.31% in the December 2024 quarter
Net profit of Gujarat Themis Biosyn declined 0.31% to Rs 12.97 crore in the quarter ended December 2024 as against Rs 13.01 crore during the previous quarter ended December 2023. Sales rose 1.91% to Rs 39.52 crore in the quarter ended December 2024 as against Rs 38.78 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales39.5238.78 2 OPM %47.7245.56 - PBDT18.9618.67 2 PBT17.4017.69 -2 NP12.9713.01 0 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Gujarat Themis Biosyn to convene board meeting
Gujarat Themis Biosyn will hold a meeting of the Board of Directors of the Company on 14 February 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Board approved merger of Gujarat Themis Biosyn with Themis Medicare
The Board of Directors of Gujarat Themis Biosyn (GTBL) and Themis Medicare (TML) have approved a Scheme of Amalgamation of Gujarat Themis Biosyn with Themis Medicare. The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL, the stock exchanges, SEBI, NCLT and other regulatory approvals as may be required. This amalgamation will result in consolidation of businesses and integration of the entire product value chain under a single amalgamated entity, leading to significant synergies. Under the scheme, TML will issue and allot 118 equity shares of the face value of Re. 1 each, credited as fully paid-up, for every 100 equity shares of the face value of Re. 1 each fully paid-up, held by shareholders in GTBL.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Gujarat Themis Biosyn standalone net profit declines 15.71% in the September 2024 quarter
Net profit of Gujarat Themis Biosyn declined 15.71% to Rs 10.57 crore in the quarter ended September 2024 as against Rs 12.54 crore during the previous quarter ended September 2023. Sales declined 12.19% to Rs 34.72 crore in the quarter ended September 2024 as against Rs 39.54 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales34.7239.54 -12 OPM %44.3542.26 - PBDT15.6417.76 -12 PBT14.2016.88 -16 NP10.5712.54 -16 Powered by Capital Market - Live
7 months agoCapital Market - Live
Spotlight
Gujarat Themis' Q1 PAT falls over 25% YoY to Rs 13 crore
This decline was primarily driven by a 21.7% YoY drop in net sales to Rs 38.83 crore. Total operating expenses also decreased by 22.2% to Rs 20.28 crore in the June'24 quarter. Consequently, PBIDT decreased by 22.4% YoY to Rs 19.07 crore in Q1 FY25, with a margin of 49.11% (down from 49.57% in Q1 FY24). Further, the company's depreciation charges increased by 53.3% YoY to Rs 1.15 crore during the period under review. As a result, profit before tax fell by 25% to Rs 17.86 crore in Q1 FY25 compared to Rs 23.81 crore in the corresponding quarter of the previous year. Gujarat Themis Biosyn is engaged in the manufacturing of APIs, namely, Rifamycin S and Rifamycin O. The scrip had declined 3.91% to end at Rs 483.75 on the BSE on Friday. In the last one year, the stock of Gujarat Themis Biosyn has surged 207.26% while the benchmark Sensex had risen 21.92% in the same period. Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Board of Gujarat Themis Biosyn appoints director
The Board of Gujarat Themis Biosyn has approved the appointment of K. G. Ananthakrishnan (DIN: 00019325) as an Additional Independent Director of the Company w.e.f. 26 July 2024. Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Gujarat Themis Biosyn fixes record date for bonus issue
Gujarat Themis Biosyn has fixed 09 August 2024 as record date for issuance of bonus shares. Powered by Capital Market - Live
10 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 32.13%, vs industry avg of 9.02%
Over the last 5 years, market share increased from 0.01% to 0.05%
Over the last 5 years, net income has grown at a yearly rate of 55.96%, vs industry avg of 15.29%